Land: Irland
Språk: engelsk
Kilde: HPRA (Health Products Regulatory Authority)
Pantoprazole
KRKA, d.d., Novo mesto
A02BC; A02BC02
Pantoprazole
20 milligram(s)
Gastro-resistant tablet
Product not subject to medical prescription
Proton pump inhibitors; pantoprazole
Not marketed
2013-11-25
PACKAGE LEAFLET: INFORMATION FOR THE USER NOLPACID 20 MG GASTRO-RESISTANT TABLETS pantoprazole READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. Always take this medicine exactly as described in this leaflet or as your doctor or pharmacist has told you. - Keep this leaflet. You may need to read it again. - Ask your pharmacist if you need more information or advice. - If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. - You must talk to a doctor if you do not feel better or if you feel worse after 2 weeks. WHAT IS IN THIS LEAFLET 1. What Nolpacid is and what it is used for 2. What you need to know before you take Nolpacid 3. How to take Nolpacid 4. Possible side effects 5. How to store Nolpacid 6. Contents of the pack and other information 1. WHAT NOLPACID IS AND WHAT IT IS USED FOR Nolpacid contains the active substance pantoprazole, which blocks the ‘pump’ that produces stomach acid. Hence it reduces the amount of acid in your stomach. Nolpacid is used for the short-term treatment of reflux symptoms (for example heartburn, acid regurgitation) in adults. Reflux is the backflow of acid from the stomach into the gullet (“foodpipe”), which may become inflamed and painful. This may cause you symptoms such as a painful burning sensation in the chest rising up to the throat (heartburn) and a sour taste in the mouth (acid regurgitation). You may experience relief from your acid reflux and heartburn symptoms after just one day of treatment with Nolpacid, but this medicine is not meant to bring immediate relief. It may be necessary to take the tablets for 2–3 consecutive days to relieve the symptoms. You must talk to a doctor if you do not feel better or if you feel worse after 2 weeks. 2. WHAT YOU NEED TO KNOW BEFORE YOU TAKE NOLPACID DO NOT TAKE NOLPACID: - if you are allergic to pantoprazole or any of the other ingredients of this medicine (l Les hele dokumentet
Health Products Regulatory Authority 25 March 2024 CRN00DTHL Page 1 of 9 SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Nolpacid 20 mg gastro-resistant tablets 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each gastro-resistant tablets contains 20 mg pantoprazole as pantoprazole sodium sesquihydrate. Excipient with known effect: sorbitol (E420): 18 mg/tablet For the full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Gastro-resistant tablet. Gastro-resistant tablets are light yellowish brown, oval (3 mm x 9 mm), slightly biconvex film-coated tablets. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Short-term treatment of reflux symptoms (e.g. heartburn, acid regurgitation) in adults. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Posology The recommended dose is 20 mg pantoprazole (one tablet) per day. It might be necessary to take the tablets for 2-3 consecutive days to achieve improvement of symptoms. Once complete relief of symptoms has occurred, treatment should be discontinued. The treatment should not exceed 4 weeks without consulting a doctor. If no symptom relief is obtained within 2 weeks of continuous treatment, the patient should be instructed to consult a doctor. _Special populations_ No dose adjustment is necessary in elderly patients or in those with impaired renal or liver function. _Paediatric population_ Nolpacid is not recommended for use in children and adolescents below 18 years of age due to insufficient data on safety and efficacy. Method of administration Nolpacid 20 mg gastro-resistant tablets should not be chewed or crushed, and should be swallowed whole with liquid before a meal. 4.3 CONTRAINDICATIONS Hypersensitivity to the active substance or to any of the excipients listed in section 6.1. Co-administration of pantoprazole is not recommended with HIV protease inhibitors for which absorption is dependent on acidic intragastric pH such as atazanavir, nelfinavir; due to significant reduction in their bioavailability (see section 4.5). Health Products Regulat Les hele dokumentet